Study title |
SLT for PACG Multi-centre Study |
|||||
Type |
Prospective Effect of SLT in specific subgroups of patients with glaucoma |
|||||
Number of patients |
15 | 15 | 30 | 30 | 30 | 30 |
Primery investigator |
Ma. Cecilia Aquino | Wong Hon Tym | Ho Ching Lin | Mario Aquino | Prin Rojanapongpun | Jimmy S.M. Lai |
Secondary investigators |
||||||
Contact informaion |
Hon_Tym_Wong@ttsh.com.sg |
|||||
Place |
National University Hospital | Tan Tock Seng Hospital | Singapore National Eye Centre | St. Luke's Medical Center, | Chulalongkorn Hospital, | United Christian Hospital |
Town |
Singapore | Singapore | Singapore | Manila | Bangkok | Hong Kong |
Country |
Singapore | Singapore | Singapore | Philippines | Thailand | Chine |
Start date |
Jul-05 | aug-05 | Oct-05 | Jul-05 | Sep-05 | Jul-05 |
Expected completion date |
Jul-06 | Aug-06 | Aug-06 | Jul-06 | Sep-06 | Jul-06 |
Expected publication date |
||||||
Purpose |
To investigate the effects of Selective Laser Trabeculoplasty (SLT) as a treatment of Primary Angle Closer glaucoma (PACG) | |||||
Method |
Patients with PACG, a patent peripheral iridectomy and a clear view of at least 90 degrees of the pigmented trabecular meshwork were treated by SLT covering all the visible meshwork | |||||
Preliminary Results |
The mean baseline IOP was 24.1±2.1 mmHg. In the 42 eyes that reached one month follow up the average IOP was 19.6±2.7 mmHg (19% reduction). At this time point there was a hypotensive response of 2 mmHg or more in all but 4 eyes (90%). At three month the average IOP in 26 eyes was 19.3±3.0 (19% reduction) and there was an IOP reduction of 2 mmHg or over in 85% of the eyes. Fifteen eyes reached 6 months follow up with an average IOP of 19.3±1.8 mmHg (20% reduction). There was a 2 mmHg reduction of 2 mmHg or more in all eyes but one (93% reduction).There were no significant complications. | |||||
Conclusion |
SLT seems to be an safe, effective and simple method of treating eyes with PACG when a sufficient extent of the angle are visible. | |||||
Note from the Authors: No financial interest with Ellex
SLT for PACG Multicentre Study